Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1405 plus gemcitabine and cisplatin in advanced triple-negative breast cancer
CTR20181515Phase 2Terminated
- Sponsor
- Zhixiang Jintai
- Start
- Apr 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GR-1405 in triple-negative breast cancer (TNBC), sponsored by Zhixiang Jintai. Started Apr 2020; status: terminated.
02
Drugs
GR-1405
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20181515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181515.